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nterest in the subjective well-being (SW) of psy-
chiatric patients has significantly increased over recent
years.While,for a long time,symptom reduction alone was
the most essential outcome parameter,more detailed suc-
cess criteria are now being implemented,approximately 50
years after the introduction of neuroleptic treatment.
Considering the extensive use of typical neuroleptics over
the last decades,surprisingly little evaluation of patients’
subjective complaints while being medicated has been per-
formed.
1-6 In terms of tolerability,investigators focused on
motor symptoms when looking at drug-induced complaints
and reasons for noncompliance.With the development of
atypical antipsychotics, treatment goals became more
ambitious,the patient’s perspective was considered more,
and complaints such as affective blunting and cognitive
slowing,as well as volition and loss of spontaneity,received
greater interest.
7-12These emotional restrictions have been
described as “neuroleptic dysphoria,”“pharmacogenetic
depression,”“akinetic depression,”“neuroleptic depres-
sion,”and “neuroleptic-induced anhedonia.”
13
The increased interest in subjective well-being was not
only due to a conceptual shift in therapeutic outcome cri-
teria:
• Studies on subjective well-being disproved the former
belief that schizophrenic patients are not able to reli-
ably assess their SW. The majority of schizophrenic
patients, if not acutely psychotic or suffering from
severe cognitive impairment,are able to complete self-
rating scales in a consistent and reliable manner.
14-17
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The patients’ perspective of antipsychotic treatment was
largely neglected for a long period. It has only been dur-
ing the last 10 years, with the development of atypical
antipsychotics, that scientific interest in this issue has
markedly increased. Numerous studies have shown that
the majority of schizophrenic patients are able to fill out
a self-rating scale in a meaningful way, and several self-
report scales with sufficient internal consistency and
good construct validity have been developed. The effects
of antipsychotic treatment on psychopathology and on
subjective well-being (SW) are not strongly related; the
perspectives of the patient and his/her psychiatrist
markedly differ. Recent research indicates that SW/qual-
ity of life, much more improved by atypical than by typ-
ical antipsychotics, has a strong impact on compliance,
as well as on the chance of achieving remission. The data
strongly suggest that a systematic evaluation of the
patient’s perspective of antipsychotic treatment is mean-
ingful and necessary to increase compliance, functional
outcome, and long-term prognosis.    
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:131-136.•The impact of antipsychotic drugs on SW,together with
the quality of the doctor–patient relationship,is one of
the two agreed major determinants for medication
compliance.
18-23
Despite significant advances in the pharmacotherapy of
schizophrenia,noncompliance,particularly in long-term
treatment,remains a major problem.Rates of noncom-
pliance vary because of inconsistent definitions and het-
erogeneous samples;studies show that 25% to 70% of all
schizophrenic patients are noncompliant.
18-20,24Although
compliance somewhat improved under treatment with
atypical antipsychotics, adherence rates at 6 and 12
months were only moderately higher compared with
patients receiving typical agents.
25 Since noncompliance
is one of the most important risk factors for relapse,
18
enhanced medication adherence is an urgent task.
Due to the advances in psychopharmacological as well as
in psychosocial/psychoeducational treatments,chances
for better long-term prognosis have been improved,and
remission has become a major goal in the treatment of
schizophrenia. Most recently, the Remission in
Schizophrenia Working Group published a consensus
statement on definition criteria and time thresholds of
remission in schizophrenia.
30 The European
Schizophrenia Outpatient Health Outcomes (SOHO)
study
26-29 was one of the first to assess these criteria,
including a self-rating,in a large sample of patients.
Measurement of subjective well-being
Subjective well-being is a major component of quality of
life,
31 influenced by the pharmacological and/or psy-
chosocial treatment as well as by the illness itself.A mul-
titude of components, for example patients’ attitudes
toward medication or other nonpharmacological factors,
possibly interfere when their subjective experience of
neuroleptic drugs is investigated.
Naber suggested a model consisting of five dimensions
of SW:emotional regulation,self-control,mental func-
tioning, social integration, and physical functioning.
15
Lambert et al
14 combined this concept with six influenc-
ing factors:psychopathology and symptomatic improve-
ment,physical side effects and associated distress,atti-
tudes toward pharmacological treatment and insight,psy-
chosocial factors,phase,and severity of illness.One major
impetus for this research was the sometimes marked sub-
jective improvement,when patients were switched from
typical antipsychotics to clozapine.
32 Similarly to the first
trial,quality of life was an outcome criterion to assess the
improvement by clozapine.
33
The Subjective Well-being under Neuroleptic treatment
(SWN) is a self-rating Likert scale with 20 items (10 pos-
itive,10 negative) and good psychometric properties.
18,34
Recently, an algorithm has been developed to exclude
patients who are unable to understand the items or to
reliably fill out the scale,based on analyzing mean dif-
ferences between negative and positive items for the
individual subscores (S. Moritz, unpublished data).
Starting with the pioneer work of the Drug Attitude
Inventory of Hogan et al,
35 there now exist,together with
the SWN,several self-rating instruments to investigate
the patients’ perspective of antipsychotic treatment.
32
Psychopathology and subjective well-being
The relationship between psychopathology,as shown with
the Positive and Negative Syndrome Scale (PANSS),and
the subjective well-being,as measured with the SWN,was
investigated in several trials.
15,35-37The total score,as well as
the subscales were only moderately correlated with the
PANSS scores (r=-0.1 to –0.5) with stronger relationships
to the negative and global score than to the positive score.
The highest correlations (r=-0.4 to –0.5) were related to
the severity of depression and anxiety. Regarding the
impact of side effects,Lambert et al
38 found,in a study in
213 patients treated with typical neuroleptics,that sexual
dysfunctions and extrapyramidal and psychic side effects
were rated as subjectively more distressing than vegeta-
tive side effects and sedation.
In a study by de Haan et al
39 it was shown that dosage of
medication leading to dopamine (D2) receptor blockade
should be carefully evaluated, since it is most likely
responsible for neuroleptic dysphoria, even in the
absence of motor side effects.
40,41 The relationship
between SWN and striatal D2 receptor occupancy was
investigated in 22 schizophrenic patients,clinically stable
under either 14.7 mg of olanzapine or 4.1 mg of risperi-
done. It was demonstrated that in the absence of
extrapyramidal symptoms,higher striatial D2-receptor
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Selected abbreviations and acronyms
PANSS Positive and Negative Syndrome Scale
SOHO Schizophrenia Outpatient Health Outcomes study
SUD substance use disorder
SW subjective well-being
SWN Subjective Well-being under Neuroleptic treatmentoccupancy as measured by single photon-emission com-
puted tomography (SPECT) was related to reduced
SWN,negative symptoms,and depression (P<0.01).
Atypical antipsychotics, subjective 
well-being, and compliance
Naber
15 investigated the subjective perception of neu-
roleptic treatment with the SWN and found it to be sig-
nificantly related to noncompliance.Forty-eight patients
rated their SWN prior to discharge from inpatient treat-
ment.Six months later,14 patients were noncompliant.
Compared with 34 patients who remained compliant,
their SWN at discharge was significantly lower (P<0.05).
However, the psychiatrists did not see a difference
between future compliant or noncompliant patients;the
PANSS scores did not differentiate between both groups.
In another patient population, it was shown that the
SWN of 28 patients treated with the atypical antipsy-
chotic clozapine because of therapy resistance or motor
side effects was,despite negative selection,significantly
better than the SWN score of 38 patients under classical
neuroleptics (P=0.03).
In a later study,olanzapine and clozapine were compared
in a double-blind,controlled trial in 114 patients,over a
26-week period.
37 Regarding SWN,the total score–as well
as all subscores,excluding mental functioning–showed
a significant relationship between low SWN and non-
compliance (P<0.005 – P<0.01).Again,this study showed
that the improvement of SWN and of PANSS are not
strongly related (r=-0.3 to -0.4).
The SOHO study also found a relevant relationship
between subjective well-being and compliance.It is a 3-
year investigation of the health outcomes associated with
antipsychotic treatment in Europe.
26-29 Data were col-
lected in a prospective, nonrandomized observational
study of 10 972 patients with schizophrenia,recruited in
10 European countries between January and December
2001.In the German study population with 2960 patients,
SWN was used to assess the patients’ perspective. At
baseline,patients and physicians categorized compliance
as “almost always compliant,” “partly compliant,” or
“almost never compliant.” The relationship between
changes in compliance (improvement n=225,no change
n=1366, worsening n=78) and clinical variables were
assessed by factor analysis.This revealed the strongest
correlations for SWN (r
2=0.866),followed by symptoms
(r
2=0.772) and side effects (r
2=0.480) (Karow et al,
unpublished data).SW seems to be of potent influence
on adherence during maintenance treatment,but not in
the acute phase,as Mutsatsa et al
43 did not find a signifi-
cant relationship between SWN and early medication
adherence in 101 first-episode patients.
Numerous studies show the advantages of atypical ver-
sus typical antipsychotics,and these advantages are most
prominent from the patients’ perspectives: Atypical
antipsychotics improve subjective quality of life more
than typical antipsychotics,
44,45 subjective response is sig-
nificantly better under atypical compared with typical
drugs,
46 and,not surprisingly,switching from a typical to
atypical antipsychotic is associated with a marked sub-
jective improvement.
47,48
Subjective well-being as a remission 
criterion in the SOHO study
In the SOHO study,SWN was used as an important sin-
gle component of the complete remission criterion,
according to the new consensus statement on criteria and
the time frame of remission in schizophrenia published
by the Remission in Schizophrenia Working Group.
30 In
contrast to previous definitions,the consensus included
the incorporation of subjective rating next to sustained
symptomatic (ie,positive,negative,and cognitive symp-
toms) as well as functional remission (ie, activities of
daily living,employment).
49-57
Remission criteria and predictor variables were assessed
at baseline,at 3,6,12,18,and 24 months with standard-
ized scales.Complete remission was defined as patients
fulfilling all criteria for (i) symptomatic,(ii) functional,
and (iii) subjective well-being over a period of at least 6
months (ie, at the 18-month and 24-month visits).
Symptomatic remission was defined as receiving a
Clinical Global Impressions Scale (CGI)-Schizophrenia
score
58 of no worse than “mild” (≤3) in assessments of
overall severity,positive,and cognitive subscores and a
score of no worse than “moderate”(≤4) in the negative
subscore.Functional remission was defined as a positive
occupational/vocational status,ie,paid or unpaid,full- or
part-time employment,being an active student or head
of a household with an employed partner,and indepen-
dent living, ie, living alone, living with a partner, living
with peers.Subjective well-being was met if a SWN total
score of ≥ 80 points was achieved.
Predictor variables were (i) baseline predictors,(ii) early
course of treatment predictors defined as fulfilled remis-
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133sion criteria at 3 months, and (iii) course of treatment
predictors defined as variables assessed continuously
throughout the complete 24-month period.
The baseline predictors were (i) age,gender,and dura-
tion of illness,(ii) symptomatic status assessed with the
expanded version of the CGI-Schizophrenia including an
overall severity of illness score and 4 subscores for the
severity of positive,negative,cognitive,and depressive
syndromes,(iii) functional variables included the occu-
pational/vocational status and independent living
assessed in yes/no categories,(iv) subjective well-being
assessed with the SWN.The early course of treatment
predictors were early symptomatic,functional,and sub-
jective well-being remission at 3 months.The course of
treatment predictors were compliance with antipsychotic
medication, (noncompliance was defined as missing
≥50% of medication over at least 4 weeks) and comorbid
substance use disorder (SUD) according to Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV) cri-
teria, categorized into (i) no SUD; (ii) remitted SUD
(remission during follow-up with SUD at baseline);and
(iii) persistent SUD.
Lambert et al (unpublished data) found that 50% of the
patients achieved symptomatic remission and about 40%
subjective well-being remission,whereas only one third
sustained functional remission.Including symptomatic
and functional criteria,19% achieved complete remission
in the SOHO study;following the consensus statement
including the subjective quality of life, remission rate
decreased to 14%.It is of particular interest that 32% of
all patients achieved none of the three remission criteria.
First antipsychotic treatment proved to be a predictor of
all remission criteria. Similarly to the study by
Robinson,
52 the functional remission criterion of 24.5%
was the main barrier in achieving complete remission.
Consistent with previous studies,
52,56 early remission
within the first 3 months predicted all remission criteria
including complete remission.Therefore,early detection
of incomplete remission or treatment resistance and sub-
sequent treatment adaptation are mandatory in the treat-
ment of multiple-episode patients as well as first-episode
patients.
61 Lambert et al found specific predictors of
remission components in the SOHO analysis.Persistent
SUD when compared with no SUD was associated with
a decreased probability of symptomatic remission,while
baseline SUD was not found to have significant influence
on symptomatic remission,consistent with previous find-
ings.
60 Similar to findings from many previous studies,
medication noncompliance was associated with sympto-
matic nonremission.
Conclusion
For a long period,many psychiatrists believed that they
knew their patients well enough not to need additional
self-ratings by the patients. However, numerous trials
have revealed that both perspectives differ markedly
regarding the relevance of side effects or success of
antipsychotic treatment.Subjective well-being is at least
a valuable addition to objective (?) psychopathology,and
should become an integral part of shared decision-mak-
ing.A better consideration of the patients’ perspective
can improve therapeutic alliance,medication adherence,
and,finally,the long-term prognosis. ❏
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El proyecto MATRICS del NIMH para 
desarrollar agentes que mejoren la 
cognición en la esquizofrenia
El Instituto Nacional de Salud Mental de los Estados
Unidos ha financiado una iniciativa para facilitar el
desarrollo de psicofármacos para mejorar la neuro-
cognición en pacientes con esquizofrenia. Esto se
ha llevado a cabo  mediante un proceso consen-
suado en que se han incluido representantes del
mundo académico, de la industria farmacéutica y
del gobierno. El grupo ha señalado los obstáculos
para el desarrollo de fármacos, los que incluyen: (i)
la falta de un instrumento bien aceptado para
medir la neurocognición en los ensayos clínicos, (ii)
la falta de consenso respecto al mejor o los mejores
objetivos moleculares para el desarrollo de fárma-
cos, (iii) la falta de consenso respecto al diseño de
ensayos óptimos tanto para la comedicación que
mejore la cognición cuando se asocia a un antipsi-
cótico como para un fármaco de amplio espectro
que mejore la cognición y trate la psicosis y (iv) los
procedimientos de las agencias reguladoras, como
la FDA de los Estados Unidos, para aprobar y clasi-
ficar un nuevo fármaco.    
Impact sur l’observance et la rémission du
bien-être subjectif ressenti sous traitement
neuroleptique.
Le point de vue du patient sur le traitement anti-
psychotique a été très négligé pendant une longue
période. C’est seulement depuis ces 10 dernières
années, avec le développement des antipsycho-
tiques atypiques, que l’intérêt scientifique sur cette
question s’est accru considérablement. De nom-
breuses études ont montré que la majorité des
patients schizophrènes est capable de remplir une
échelle d’auto-appréciation de façon intelligible et
plusieurs échelles de ce type avec une cohérence
interne suffisante et une bonne validité de
construction ont été développées. Les effets du trai-
tement antipsychotique sur la psychopathologie et
sur le bien-être subjectif (BS) sont peu rapportés ;
les points de vue du patient et de son psychiatre
diffèrent sensiblement. Des recherches récentes
montrent que le rapport BS/qualité de vie, plus
amélioré par les antipsychotiques atypiques que
typiques, influe beaucoup sur l’observance comme
sur la probabilité de rémission. Les données suggè-
rent fortement que l’évaluation systématique du
traitement antipsychotique par le patient est signi-
ficative et nécessaire pour augmenter l’observance,
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